The Sapphire Star Partners LP Holds Position in Illumina, Inc. (ILMN)

The Sapphire Star Partners LP Holds Position in Illumina, Inc. (ILMN)

Other institutional investors have also recently made changes to their positions in the company. Dimensional Fund Advisors LP boosted its position in shares of Illumina by 0.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 255,908 shares of the life sciences company’s stock valued at $32,768,000 after buying an additional 2,258 shares in the last quarter. RMB Capital Management LLC purchased a new position in shares of Illumina during the fourth quarter valued at about $219,000. Perigon Wealth Management LLC boosted its position in shares of Illumina by 8.2% in the fourth quarter. Perigon Wealth Management LLC now owns 8,418 shares of the life sciences company’s stock valued at $1,418,000 after buying an additional 641 shares in the last quarter. Kentucky Retirement Systems purchased a new position in shares of Illumina during the fourth quarter valued at about $1,365,000. Finally, Kentucky Retirement Systems Insurance Trust Fund purchased a new position in shares of Illumina during the fourth quarter valued at about $609,000. 93.68% of the stock is currently owned by institutional investors.

Sapphire Star Partners LP continued to hold its position in shares of Illumina, Inc. (NASDAQ:ILMN) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,200 shares of the life sciences company’s stock at the end of the second quarter. Sapphire Star Partners LP’s holdings in Illumina were worth $208,000 at the end of the most recent reporting period.

Shares of Illumina, Inc. (NASDAQ:ILMN) traded up 13.76% during mid-day trading on Wednesday, reaching $196.00. 3,501,548 shares of the company’s stock traded hands. Illumina, Inc. has a 1-year low of $119.37 and a 1-year high of $197.56. The company has a market capitalization of $28.62 billion, a P/E ratio of 39.67 and a beta of 0.83. The firm has a 50-day moving average price of $174.66 and a 200-day moving average price of $171.89.

Illumina (NASDAQ:ILMN) last issued its earnings results on Tuesday, August 1st. The life sciences company reported $0.82 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.68 by $0.14. The firm had revenue of $662 million for the quarter, compared to the consensus estimate of $642.38 million. Illumina had a return on equity of 21.21% and a net margin of 30.75%. The company’s revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the business posted $0.86 EPS. On average, equities research analysts forecast that Illumina, Inc. will post $3.63 earnings per share for the current fiscal year.

Several equities analysts have issued reports on ILMN shares. Zacks Investment Research raised shares of Illumina from a “hold” rating to a “buy” rating and set a $191.00 price objective on the stock in a research note on Tuesday, April 4th. Vetr raised shares of Illumina from a “buy” rating to a “strong-buy” rating and set a $190.90 price target on the stock in a research note on Tuesday, April 4th. Leerink Swann reaffirmed a “buy” rating on shares of Illumina in a research note on Wednesday, April 5th. TheStreet raised shares of Illumina from a “c+” rating to a “b” rating in a research note on Thursday, April 6th. Finally, Bank of America Corporation upped their price target on shares of Illumina from $175.00 to $195.00 and gave the stock a “buy” rating in a research note on Tuesday, April 11th. Three research analysts have rated the stock with a sell rating, nine have given a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. The company has an average rating of “Hold” and an average target price of $174.17.

In related news, Director Jay T. Flatley sold 20,000 shares of the firm’s stock in a transaction on Tuesday, May 9th. The stock was sold at an average price of $184.14, for a total transaction of $3,682,800.00. Following the sale, the director now owns 539,176 shares of the company’s stock, valued at approximately $99,283,868.64. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Michel Bouchard sold 5,740 shares of the firm’s stock in a transaction on Tuesday, May 9th. The shares were sold at an average price of $184.68, for a total value of $1,060,063.20. Following the sale, the insider now directly owns 22,255 shares in the company, valued at approximately $4,110,053.40. The disclosure for this sale can be found here. In the last ninety days, insiders sold 123,639 shares of company stock worth $21,980,677. Company insiders own 1.60% of the company’s stock.

Illumina Company Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Related posts

Leave a Comment